Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Genetically informed search for potential osteoarthritis drug targets across the proteome.

Created on 13 Nov 2026

Authors

Weijie Liu, Benjamin P Zuckerman, Art Schuermans, Gisela Orozco, Michael C Honigberg, John Bowes, Terence W O'Neill, Sizheng Steven Zhao

Published in

Osteoarthritis and cartilage open. Volume 8. Issue 4. Pages 100890. Epub Oct 24, 2026.

Abstract

Osteoarthritis (OA) is a leading cause of disability, yet no licensed therapies can prevent or slow its progression. We aimed to identify potential disease-modifying OA drug (DMOAD) targets by integrating genetic and differential protein abundance (DPA) evidence.
We evaluated genetically predicted perturbations of plasma protein levels using cis-protein quantitative trait loci (cis-pQTLs) across three European cohorts (UK Biobank Pharma Proteomics Project, deCODE, and Fenland) and outcome data from the Genetics of Osteoarthritis Consortium across 11 OA phenotypes. Following limit-of-detection and missingness filtering, DPA evaluated 2133 proteins in 7186 prevalent OA cases and 29,584 controls from UK Biobank. MR-prioritised proteins were further assessed using summary-data-based Mendelian randomisation (SMR) with OA joint-tissue eQTL data, alongside pathway, protein-interaction, and druggability analyses.
Cis-MR and colocalisation prioritised 81 proteins, of which 30 showed joint-tissue transcriptomic support in SMR analyses. DPA identified 1436 proteins associated with ≥1 OA phenotype, of which 1314 (91.5%) retained significance in sensitivity analyses. Seventeen proteins had matched MR and DPA support, including three Tier 1 druggable targets (DLK1, SOST, and TNFRSF9); seven of these had SMR support. EHBP1, LGALS3, and OGN showed concordant DPA and MR effects and cross-platform evidence. EHBP1, PCSK7 and ITIH4 emerged as under-recognised candidates. Pathway analyses recapitulated established OA processes, while drug enrichment identified hypothesis-generating compounds.
Integration of cis-MR, colocalisation, DPA, and tissue-specific transcriptomic evidence prioritised several potential OA therapeutic targets. DLK1, LGALS3, OGN and EHBP1 emerged as high-priority candidates, while EHBP1, PCSK7 and ITIH4 represent under-recognised candidates warranting functional investigation.

PMID:
43022691
Bibliographic data and abstract were imported from PubMed on 13 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 12
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement